Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August

The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a Portfolio of the 4 largest such companies.